Table V.
Analysis of the distribution of the XRCC1 and XPD triple-location genotypes in hepatocellular carcinoma and control groups stratified according to HBV antigen.
| Genotype | HBsAg (+)
|
HBsAg (−)
|
||||||
|---|---|---|---|---|---|---|---|---|
| HCC group (n) | Control group (n) | OR (95% CI) | P-values | HCC group (n) | Control group (n) | OR (95% CI) | P-values | |
| XRCC1 Arg194Trp | ||||||||
| CC | 93 | 100 | 1.00 | 0.27 | 26 | 28 | 1.00 | 0.85 |
| CT+TT | 110 | 94 | 1.26 (0.89–1.76) | 23 | 28 | 0.89 (0.46–1.71) | ||
| XRCC1 Arg280His | ||||||||
| GG | 153 | 163 | 1.00 | 0.04 | 40 | 43 | 1.00 | 0.63 |
| GA+AA | 50 | 31 | 1.68 (1.08–2.60) | 9 | 13 | 0.74 (0.33–1.66) | ||
| XPD Asp312Asn | ||||||||
| GG | 153 | 166 | 1.00 | 0.01 | 39 | 41 | 1.00 | 0.76 |
| GA+AA | 50 | 28 | 1.96 (1.24–3.10) | 10 | 15 | 1.13 (0.96–1.79) | ||
OR values were adjusted by gender, age, tobacco smoking, alcohol consumption and family history.